探索药物发现中化合物选择中药学向中介低等离子体暴露对化合物选择的影响 - 一种建模方法
Min Xu1, Duxin Sun2, Guohua An3
1Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, 115 S Grand Ave, Iowa City, Iowa, 52242, USA.
低药物开发成功可能源于目标介导的低血暴露. 传统的药理动力学标准可能会错误地选择化合物,忽视具有高标结合但低血度的候选物.
科学领域:
- 药理动力学 药理动力学
- 药物开发 药物开发
- 计算建模 计算建模
背景情况:
- 小分子药物开发的成功率很低,临床前阶段经常被忽视.
- 目标介导的低血暴露是一个很少讨论的因素,有助于导致化合物错误选择.
- 传统的药理动力学 (PK) 标准可能会无意中排除最佳候选药物.
研究的目的:
- 评估目标介导的低血暴露对化合物选择的影响.
- 为评估药物度-时间概况建立和使用最小生理学基础的药理动力学 (mPBPK) 模型.
- 调查传统的PK标准是否导致有前途的候选药物的错误选择.
主要方法:
- 开发一个最小生理学基础的药理动力学 (mPBPK) 模型.
- 模拟虚拟系列类似物在血和组织中的度-时间概况.
- 使用四种氨酸激酶抑制剂 (阿法替尼布,达沙替尼布,格菲提尼布,索拉费尼布) 和室内动物PK/组织分布数据对mPBPK模型进行部分验证.
主要成果:
- 模拟表明,具有更高标结合的化合物由于标介导的组织保留,表现出较低的血暴露.
- 在研究的TKI中,关联率常数 (Kass) 和组织保留度量 (AUC_高透组织/AUC_血) 之间发现了强烈的相关性.
- 估计的卡斯值分别为49.8小时-1,31.4小时-1,8.58小时-1和1.91小时-1的阿法替尼布,达沙替尼布,格菲替尼布和索拉芬尼布.
结论:
- 目标介导的低血暴露是化合物选择时需要考虑的关键因素.
- 需要高血暴露的传统PK标准可能导致有效药物候选者的错误选择.
- mPBPK建模为评估目标中介药物处置和优化临床前药物开发提供了有价值的工具.
更多相关视频
08:46Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
Published on: April 21, 2022
10:07High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Drug Discovery: Overview
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
